Quark Pharmaceuticals to Serve as NorthStar's China Registration Agent for Actinium-225

NorthStar Medical Technologies of the US and Quark Pharmaceuticals signed a strategic cooperation agreement on October 14, 2026, covering registration of no-carrier-added actinium-225 (n.c.a. Ac-225) in China. Quark will act as NorthStar's registration agent in China, supporting IND filings for drug developers running clinical studies with NorthStar's n.c.a. Ac-225. Registration work under the arrangement now proceeds.